Alnylam Pharmaceuticals Inc’s recently made public that its CSO & EVP, Head of Research Fitzgerald Kevin Joseph unloaded Company’s shares for reported $0.47 million on Mar 03 ’25. In the deal valued at $243.73 per share,1,911 shares were sold. As a result of this transaction, Fitzgerald Kevin Joseph now holds 14,345 shares worth roughly $3.34 million.
Then, Fitzgerald Kevin Joseph sold 844 shares, generating $203,532 in total proceeds. Upon selling the shares at $241.15, the CSO & EVP, Head of Research now owns 13,501 shares.
Before that, Tanguler Tolga sold 471 shares. Alnylam Pharmaceuticals Inc shares valued at $114,820 were divested by the EVP, Chief Commercial Officer at a price of $243.78 per share. As a result of the transaction, Tanguler Tolga now holds 28,011 shares, worth roughly $6.53 million.
Wolfe Research downgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Underperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Goldman also remained covering ALNY and has increased its forecast on August 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Goldman revised its rating on February 16, 2024. It rated ALNY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -4.68% to $233.07. Over the last five days, the stock has lost -4.30%. Alnylam Pharmaceuticals Inc shares have fallen nearly -0.95% since the year began. Nevertheless, the stocks have risen 55.73% over the past one year. While a 52-week high of $304.39 was reached on 01/27/25, a 52-week low of $141.98 was recorded on 01/06/25. SMA at 50 days reached $254.24, while 200 days put it at $247.90.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 229.16, which if violated will result in even more drops to 225.26. On the upside, there is a resistance level at 240.65. A further resistance level may holdings at 248.24. The Relative Strength Index (RSI) on the 14-day chart is 33.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.03%. Stochastics %K at 25.37% indicates the stock is a holding.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
